Tsveta Milanova, the Chief Commercial Officer at Agios Pharmaceuticals, filed a Form 4 disclosing the sale of 3,262 shares of common stock on April 2, 2026. The transaction was executed at a price of $34.71 per share and totaled approximately $113,224. The filing states the sale was related to covering tax liabilities arising from the vesting of performance share units.
That same day Milanova exercised options to acquire 8,500 shares of Agios common stock at an exercise price of $0. The performance share units in question vested following the company’s attainment of a regulatory milestone, as noted in the Form 4 filing.
The sale occurred while Agios shares were trading near $34.80, with the stock having recorded a 19% advance over the prior week. The insider disclosure and option exercise coincided with company-level developments on the regulatory front.
Agios recently announced its intent to pursue accelerated approval for mitapivat in the treatment of sickle cell disease after a pre-submission meeting with the U.S. Food and Drug Administration. In response to that regulatory decision and the perceived rise in the drug’s probability of success, BofA Securities raised its price target for Agios to $44 and maintained a Buy rating.
Truist Securities also reaffirmed a Buy rating, keeping a $39 price target for the company. Those analyst actions followed the company’s stated regulatory plans and reflect increased attention from the sell-side on Agios’ development pathway.
The broader sickle cell disease treatment landscape has also drawn analyst commentary. Stifel highlighted Fulcrum Therapeutics as remaining undervalued in light of what Stifel described as FDA flexibility in the sickle cell treatment space. Leerink Partners reiterated an Outperform rating for Fulcrum with a $47 price target. These notes underscore active analyst engagement across companies pursuing therapies in this indication.
Collectively, the insider transaction, option exercise, and the company’s regulatory move for mitapivat are part of a concentrated set of developments that have drawn both market and analyst attention to Agios and to peers operating in the sickle cell disease treatment market.